On Jun. 11, 2024, CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), to provide 665,000 pre-pandemic vaccine doses for fifteen EU and EEA Member States as well as to the “Union Civil Protection Mechanism” (rescEU). This acquisition of pre-pandemic (zoonotic) vaccine will create a stockpile of vaccines available to support the EC’s outbreak and pre-pandemic response.

Under the terms of the agreement, CSL Seqirus will deliver 665,000 doses of pre-pandemic vaccine that is well-matched to the H5 of the currently circulating H5N1 strain, to fifteen EU and EEA Member States, as well as the “Union Civil Protection Mechanism” (rescEU). In addition, the 4-year contract includes an option for participating authorities to purchase up to an additional 40 million doses of the pre-pandemic vaccine over the life of the contract.

The vaccines are being manufactured in CSL Seqirus’ European manufacturing sites in Amsterdam (for test and release) and Liverpool which utilises a scalable method of production and is one of the largest sites in Europe to manufacture seasonal influenza vaccines.